HCA Healthcare (NYSE:HCA) has been given a $104.00 target price by research analysts at Robert W. Baird in a research report issued to clients and investors on Friday. The firm currently has a “buy” rating on the stock. Robert W. Baird’s target price suggests a potential upside of 17.12% from the company’s previous close.
HCA has been the topic of several other reports. Piper Jaffray Companies reiterated a “buy” rating and issued a $92.00 target price on shares of HCA Healthcare in a report on Wednesday, October 4th. Jefferies Group cut their target price on shares of HCA Healthcare from $90.00 to $88.00 and set a “buy” rating on the stock in a report on Wednesday, November 1st. ValuEngine upgraded shares of HCA Healthcare from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. SunTrust Banks set a $105.00 target price on shares of HCA Healthcare and gave the stock a “buy” rating in a report on Thursday, December 21st. Finally, Mizuho reiterated a “buy” rating on shares of HCA Healthcare in a report on Friday, October 20th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and eighteen have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $88.70.
Shares of HCA Healthcare (NYSE:HCA) traded up $1.83 during mid-day trading on Friday, reaching $88.80. 1,830,426 shares of the company’s stock were exchanged, compared to its average volume of 1,909,435. HCA Healthcare has a 1 year low of $71.18 and a 1 year high of $91.03. The company has a market capitalization of $31,439.91, a PE ratio of 12.63, a PEG ratio of 1.19 and a beta of 0.55. The company has a current ratio of 1.68, a quick ratio of 1.41 and a debt-to-equity ratio of -6.46.
In related news, insider Michael S. Cuffe sold 2,150 shares of the firm’s stock in a transaction on Tuesday, October 17th. The shares were sold at an average price of $78.00, for a total transaction of $167,700.00. Following the sale, the insider now directly owns 12,476 shares in the company, valued at $973,128. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Victor L. Campbell sold 8,000 shares of the firm’s stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $75.82, for a total transaction of $606,560.00. Following the sale, the senior vice president now owns 127,275 shares in the company, valued at $9,649,990.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 22,700 shares of company stock worth $1,773,872. 2.90% of the stock is currently owned by company insiders.
Several large investors have recently modified their holdings of the stock. Argent Capital Management LLC increased its stake in HCA Healthcare by 1.2% in the 2nd quarter. Argent Capital Management LLC now owns 4,370 shares of the company’s stock valued at $381,000 after buying an additional 50 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its stake in HCA Healthcare by 14.0% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,163 shares of the company’s stock valued at $101,000 after buying an additional 143 shares during the last quarter. Thrivent Financial For Lutherans increased its stake in HCA Healthcare by 1.5% in the 2nd quarter. Thrivent Financial For Lutherans now owns 10,810 shares of the company’s stock valued at $943,000 after buying an additional 160 shares during the last quarter. Acrospire Investment Management LLC increased its stake in HCA Healthcare by 14.3% in the 2nd quarter. Acrospire Investment Management LLC now owns 1,600 shares of the company’s stock valued at $140,000 after buying an additional 200 shares during the last quarter. Finally, Dai Ichi Life Insurance Company Ltd increased its stake in HCA Healthcare by 1.2% in the 2nd quarter. Dai Ichi Life Insurance Company Ltd now owns 20,577 shares of the company’s stock valued at $1,794,000 after buying an additional 236 shares during the last quarter. Institutional investors and hedge funds own 75.34% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Robert W. Baird Analysts Give HCA Healthcare (HCA) a $104.00 Price Target” was reported by American Banking and Market News and is the property of of American Banking and Market News. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/01/14/robert-w-baird-analysts-give-hca-healthcare-hca-a-104-00-price-target.html.
HCA Healthcare Company Profile
HCA Healthcare, Inc, formerly HCA Holdings, Inc, is a holding company. The Company, through its subsidiaries, owns and operates hospitals and related healthcare entities. As of December 31, 2016, the Company operated in two geographically organized groups, including the National and American Groups. As of December 31, 2016, the National Group included 84 hospitals, which were located in Alaska, California, Florida, southern Georgia, Idaho, Indiana, northern Kentucky, Nevada, New Hampshire, South Carolina, Utah and Virginia.
